Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.370.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SVRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Utilize the $105 million term loan facility to support company growth initiatives and ongoing operations.
Stated as a priority in 1 quarter (2026-Q1). Operating income declined from -$30.3M in 2025-Q3 to -$40.9M in 2026-Q2 and net income declined from -$29.6M to -$40.2M over the same period. The financials show increasing losses, indicating limited progress on improving profitability while leveraging the loan facility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Leverage $105M term loan facility for growth and operations”
Complete the relocation of company headquarters to newly leased office space at 19 W. College Avenue, Yardley, PA.
Stated as a priority in 1 quarter (2026-Q1) with the lease agreement executed in March 2026 for occupancy starting July 1, 2026. This is a discrete event with no direct financial impact reported yet, so progress is on track as planned.
“Entered lease for new headquarters office space starting July 1, 2026”
Manage executive leadership transition with Robert Lutz promoted to Chief Financial and Operating Officer.
Stated as a priority in 1 quarter (2026-Q2) with the official promotion of Robert Lutz to CFO and COO in June 2026. This leadership change is recent and no financial impact is yet reported, so progress is in early stages.
“Robert Lutz promoted to Chief Financial and Operating Officer”
Obtain FDA approval for molgramostim inhalation solution (MOLBREEVI) for autoimmune PAP treatment by March 31, 2027 to trigger $75 million payment.
Stated as a priority in 1 quarter (2025-Q4) with a $75 million payment contingent on FDA approval of MOLBREEVI by March 31, 2027. This regulatory milestone remains pending with no revenue reported yet, so progress is pending.
“Agreement to receive $75 million upon FDA approval of MOLBREEVI by March 31, 2027”
Over the trailing year it converted 0.96x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.